Upcoming Webinars

Availability and Access to Innovative Therapies in Latin America
Tuesday, October 4, 2022
12:00PM EDT | 4:00PM UTC | 6:00PM CEST

Souring On SUCRAs: When Treatment Ranking Goes Wrong
Wednesday, October 5, 2022
11:00AM EDT | 3:00PM UTC | 5:00PM CEST

Health Insurance in Africa: Sustainability in Focus
Monday, October 10, 2022
9:30AM EDT | 1:30PM UTC | 3:30PM CEST

Achieving Fit for Purpose Data from Wearables for Age-Related Diseases
Tuesday, October 18, 2022
10:00AM EDT | 2:00PM UTC |  4:00PM CEST

Different HTA Perspectives on Reliably Estimating Treatment Effects 
Tuesday, November 15, 2022
11:00AM EST | 4:00PM UTC | 5:00PM CET

Strategies and Skills to Land Your First Job: The Interview
Friday, December 9, 2022
11:00AM EST | 4:00PM UTC | 5:00PM CET

 

Most Recent


Fit for Local Context? Establishing or Improving Deliberative Processes for HTA

Sep 2022

Deliberative processes for health technology assessment (HTA) are intended to facilitate participatory decision making, using discussion and open dialogue between stakeholders. Increasing attention is being given to deliberative processes, but guidance is lacking for those who wish to design or use them. Health Technology Assessment International (HTAi) and ISPOR initiated a joint task force that developed comprehensive guidance to address this gap. This webinar will be of benefit to all those involved in establishing or improving deliberative processes for HTA in local contexts.

Network Meta-Analysis - Special Topics

Sep 2022

The Statistical Methods in Health Economics and Outcome Research Special Interest Group is pleased to present two webinars on Network Meta-Analysis (NMA). The first one is an introduction to NMA by Emma Hawe. The second will cover special topics in NMA by Sofia Dias. Both webinars will be moderated by Gian Luca Di Tanna. The second webinar will feature more advanced content than the first webinar.

Clinical Outcome Assessments in the Asia Pacific Region: Strategy & Implementation

Sep 2022

Asia Pacific regional markets, including but not limited to mainland China, Japan, South Korea and Taiwan, play increasingly important roles in global clinical development. Patient-centric endpoints via clinical outcome assessments (COAs) and electronic COAs (eCOAs), are getting more and more attention in clinical research design and execution.

How Can Society Sustainably Benefit From Biosimilars? Global Learnings and Policy Recommendations for Australia

Sep 2022

This webinar leverages recent global research conducted across 17 countries to provide an overview of the challenges and solutions to ensure the biosimilar benefits are sustainably delivered to the whole society. There will be a specific focus on the issues in Australia and comparing those against examples found globally. Implications for patients, society as well as a discussion of the learnings in terms of policy provisions and best practices that can help solving these issues will also be held.

An Introduction to Network Meta-Analysis

Sep 2022

The Statistical Methods in Health Economics and Outcome Research Special Interest Group is pleased to present two webinars on Network Meta-Analysis (NMA). The first of two webinars will focus on the terms associated with network meta-analyses, how and why different comparisons are used, and the concepts, assumptions, and limitations associated with NMA. The first webinar is focused on an Introduction to NMA by Emma Hawe. The second will cover special topics in NMA by Sofia Dias. Both webinars will be moderated by Gian Luca Di Tanna.

Clinical Outcomes



Clinical Outcome Assessments in the Asia Pacific Region: Strategy & Implementation

Sep 2022

Asia Pacific regional markets, including but not limited to mainland China, Japan, South Korea and Taiwan, play increasingly important roles in global clinical development. Patient-centric endpoints via clinical outcome assessments (COAs) and electronic COAs (eCOAs), are getting more and more attention in clinical research design and execution.

Oncology Endpoints in Reimbursement Decision-Making: Are We Keeping Pace With the Science?

Jun 2022

For cancer drugs, payers often prefer to make decisions based on overall survival (OS) outcomes. However, it may take many years to collect OS data; this is particularly apparent in early-stage cancer and when an active therapy is highly effective at extending life.

The Convergence of Synthetic Data and Self-Service Analytics to Create a New RWE Model

May 2022

Real-world evidence has advanced health research over the past two or three decades. The challenges of procuring sufficient, high-quality real-world data, of unlocking the knowledge contained in the data, and of sharing information without compromising patient privacy are ever-present.

Leveraging the Value of Clinical Outcome Assessment (COA) Data Beyond Labelling

Apr 2022

Speakers will discuss the many uses of COA data gathered during patient-focused drug development, including benefit/risk evaluation, HTA, access decisions, policy decisions, and clinician and patient decision-making.


Economic Evaluation



Stakeholder Engagement in Value Assessment

Aug 2022

This is the Second webinar of the Value and Access to Innovation webseries sponsored by FIFARMA. The series are structured around FIFARMA's VAI working group workstreams: (1) Funding: what is the relation between health & the economy and how to ensure the long term healthcare system sustainability, (2) Value: what are the value frameworks used by decision makers in LatAm and what is the impact on patient access, (3) Adoption: how to ensure access for the right patient, to the right treatment, at the right time.

Financing Sustainable Healthcare Systems in Latin America

Jul 2022

This is the first webinar of the Value and Access to Innovation webseries sponsored by FIFARMA. The series are structured around FIFARMA's VAI working group workstreams.

Distributional Cost-Effectiveness Analysis to Inform Healthcare Decisions

Jun 2022

This webinar will aim to provide an educational opportunity for the ISPOR membership to learn about the methods for conducting distributional cost-effectiveness analysis (DCEA).

Oncology Endpoints in Reimbursement Decision-Making: Are We Keeping Pace With the Science?

Jun 2022

For cancer drugs, payers often prefer to make decisions based on overall survival (OS) outcomes. However, it may take many years to collect OS data; this is particularly apparent in early-stage cancer and when an active therapy is highly effective at extending life.


Health Technology Assessment



Fit for Local Context? Establishing or Improving Deliberative Processes for HTA

Sep 2022

Deliberative processes for health technology assessment (HTA) are intended to facilitate participatory decision making, using discussion and open dialogue between stakeholders. Increasing attention is being given to deliberative processes, but guidance is lacking for those who wish to design or use them. Health Technology Assessment International (HTAi) and ISPOR initiated a joint task force that developed comprehensive guidance to address this gap. This webinar will be of benefit to all those involved in establishing or improving deliberative processes for HTA in local contexts.

Financing Sustainable Healthcare Systems in Latin America

Jul 2022

This is the first webinar of the Value and Access to Innovation webseries sponsored by FIFARMA. The series are structured around FIFARMA's VAI working group workstreams.

Distributional Cost-Effectiveness Analysis to Inform Healthcare Decisions

Jun 2022

This webinar will aim to provide an educational opportunity for the ISPOR membership to learn about the methods for conducting distributional cost-effectiveness analysis (DCEA).


Real-World Data & Information Systems


Data Privacy and Digital Health: The Manufacturers/Payers Perspective

Jul 2022

The key success factor for digital health implementation is the information sharing across multiple stakeholders engaged in the clinical decision making. The COVID pandemic revealed numerous differences in how individual data are used in the process of the adoption of various digital health solutions in the healthcare systems across the globe.

The Convergence of Synthetic Data and Self-Service Analytics to Create a New RWE Model

May 2022

Real-world evidence has advanced health research over the past two or three decades. The challenges of procuring sufficient, high-quality real-world data, of unlocking the knowledge contained in the data, and of sharing information without compromising patient privacy are ever-present.

Delivering Evidence-Based Access in Rare Diseases: The Challenges in SMA

Apr 2022

This session educates about the specific challenges of rare disease treatments in an HTA and discusses how Real-World Evidence Collection can address the data gap at the time of access decision.


Patient-Centered Research



Clinical Outcome Assessments in the Asia Pacific Region: Strategy & Implementation

Sep 2022

Asia Pacific regional markets, including but not limited to mainland China, Japan, South Korea and Taiwan, play increasingly important roles in global clinical development. Patient-centric endpoints via clinical outcome assessments (COAs) and electronic COAs (eCOAs), are getting more and more attention in clinical research design and execution.

Differentiating Between Patient Preferences, Patient Reported Outcomes and Patient Engagement

Sep 2022

The webinar will define patient preferences, patient-reported outcomes and patient engagement, by describing their core defining features, how they differ from one another, and outlining the complementary roles that they may have in understanding what matters to patients. The speakers will then discuss how patient preferences, patient-reported outcomes and patient engagement can play a role in marketing authorization and health technology assessment, and ultimately, facilitate better care and access to care for patients.

Stakeholder Engagement in Value Assessment

Aug 2022

This is the Second webinar of the Value and Access to Innovation webseries sponsored by FIFARMA. The series are structured around FIFARMA's VAI working group workstreams: (1) Funding: what is the relation between health & the economy and how to ensure the long term healthcare system sustainability, (2) Value: what are the value frameworks used by decision makers in LatAm and what is the impact on patient access, (3) Adoption: how to ensure access for the right patient, to the right treatment, at the right time.

Oncology Endpoints in Reimbursement Decision-Making: Are We Keeping Pace With the Science?

Jun 2022

For cancer drugs, payers often prefer to make decisions based on overall survival (OS) outcomes. However, it may take many years to collect OS data; this is particularly apparent in early-stage cancer and when an active therapy is highly effective at extending life.

Methodical & Statistical Research



Network Meta-Analysis - Special Topics

Sep 2022

The Statistical Methods in Health Economics and Outcome Research Special Interest Group is pleased to present two webinars on Network Meta-Analysis (NMA). The first one is an introduction to NMA by Emma Hawe. The second will cover special topics in NMA by Sofia Dias. Both webinars will be moderated by Gian Luca Di Tanna. The second webinar will feature more advanced content than the first webinar.

An Introduction to Network Meta-Analysis

Sep 2022

The Statistical Methods in Health Economics and Outcome Research Special Interest Group is pleased to present two webinars on Network Meta-Analysis (NMA). The first of two webinars will focus on the terms associated with network meta-analyses, how and why different comparisons are used, and the concepts, assumptions, and limitations associated with NMA. The first webinar is focused on an Introduction to NMA by Emma Hawe. The second will cover special topics in NMA by Sofia Dias. Both webinars will be moderated by Gian Luca Di Tanna.

Distributional Cost-Effectiveness Analysis to Inform Healthcare Decisions

Jun 2022

This webinar will aim to provide an educational opportunity for the ISPOR membership to learn about the methods for conducting distributional cost-effectiveness analysis (DCEA).

Health Policy & Regulatory



How Can Society Sustainably Benefit From Biosimilars? Global Learnings and Policy Recommendations for Australia

Sep 2022

This webinar leverages recent global research conducted across 17 countries to provide an overview of the challenges and solutions to ensure the biosimilar benefits are sustainably delivered to the whole society. There will be a specific focus on the issues in Australia and comparing those against examples found globally. Implications for patients, society as well as a discussion of the learnings in terms of policy provisions and best practices that can help solving these issues will also be held.

Stakeholder Engagement in Value Assessment

Aug 2022

This is the Second webinar of the Value and Access to Innovation webseries sponsored by FIFARMA. The series are structured around FIFARMA's VAI working group workstreams: (1) Funding: what is the relation between health & the economy and how to ensure the long term healthcare system sustainability, (2) Value: what are the value frameworks used by decision makers in LatAm and what is the impact on patient access, (3) Adoption: how to ensure access for the right patient, to the right treatment, at the right time.

Data Privacy and Digital Health: The Manufacturers/Payers Perspective

Jul 2022

The key success factor for digital health implementation is the information sharing across multiple stakeholders engaged in the clinical decision making. The COVID pandemic revealed numerous differences in how individual data are used in the process of the adoption of various digital health solutions in the healthcare systems across the globe.

Study Approaches


Methods Maze: Pointers for Selecting Survival Extrapolation Models for Cancer Immunotherapy

Oct 2020

In this webinar, we will be discussing this issue in relation to cancer immunotherapy. An overview of the survival extrapolation methods which could be used for cancer immunotherapies will be presented along with an assessment of their strengths and limitations. Finally, the presenters will provide attendees with some pointers to help with the selection of appropriate survival extrapolation models for these agents.

Why and How to Use Qualitative Research Methods in Conjunction with Discrete Choice Experiments in Health Care

Jun 2020

This webinar will explore why and how to use qualitative research methods in conjunction with discrete choice experiments in healthcare. Speakers will discuss formative qualitative research for the identification and generation of attributes and levels and qualitative research for testing survey comprehension and decision-making processes.

Adding Depth to Observational Research through Data Linkage

Apr 2020

This webinar will explore the value and challenges of linking administrative claims data to additional data sources in order to provide a more comprehensive look at the patient journey through a disease state. Data linkage types, techniques and best practices will be discussed.


Epidemiology & Public Health


Stakeholder Engagement in Value Assessment

Aug 2022

This is the Second webinar of the Value and Access to Innovation webseries sponsored by FIFARMA. The series are structured around FIFARMA's VAI working group workstreams: (1) Funding: what is the relation between health & the economy and how to ensure the long term healthcare system sustainability, (2) Value: what are the value frameworks used by decision makers in LatAm and what is the impact on patient access, (3) Adoption: how to ensure access for the right patient, to the right treatment, at the right time.

Financing Sustainable Healthcare Systems in Latin America

Jul 2022

This is the first webinar of the Value and Access to Innovation webseries sponsored by FIFARMA. The series are structured around FIFARMA's VAI working group workstreams.

The Convergence of Synthetic Data and Self-Service Analytics to Create a New RWE Model

May 2022

Real-world evidence has advanced health research over the past two or three decades. The challenges of procuring sufficient, high-quality real-world data, of unlocking the knowledge contained in the data, and of sharing information without compromising patient privacy are ever-present.

ISPOR/IVI COVID Webinar #5: Using VA/HTA in Pursuing Innovation and Access in a Pandemic

Nov 2020

This capstone webinar culminates the ISPOR-IVI series with a reflection on future direction and commitment needed to improve the scientific credibility and relevance of VA/HTA to pandemic preparedness.


Specialized Treatment Areas


Health Preference Research in the Context of Gene Therapy in Rare Diseases

Sep 2021

During this webinar, the speakers will present their respective studies on gene therapy in Duchenne muscular dystrophy, spinal muscular atrophy (SMA) and hemophilia. They will discuss the importance of the disease context, the qualitative research that influenced attribute selection, the selection of health preference method and design of the health preferences’ tasks, and how the study findings relate to the potential value of gene therapy.

Biosimilars: Market Access Challenges & Opportunities Worldwide

Feb 2021

This webinar will present an insightful exchange on best practices, challenges and opportunities for market access of biosimilars in different regions worldwide.

Biosimilars: Unleashing The Potential For Improved Patient Access And Cost Savings In The United States

Oct 2020

The webinar will present an overview of societal benefits of biosimilars, how these are measured, how the United States (US) and select markets are tracking in attaining these benefits, and potential solutions for advancing the evidence of potential benefits into action.


Specific Diseases & Conditions


Challenges in Assessing the Clinical and Economic Value of Future Treatments for Alzheimer’s Disease

Feb 2021

This educational webinar will describe factors that affect the assessment of the clinical and economic value of medical innovations, highlight specific issues with relevance to the societal value of treatments for AD, and place these issues in the context of future health technology assessments for AD treatments.

Long Term Value Demonstration in Alzheimer’s Disease: Evidence Needs

Dec 2020

This educational webinar explores some of the key issues relating to long-term evidence needs within the context of HTA in AD and considers what can be done in the short, medium, and long term to address evidence needs.

Value Assessment in Alzheimer's Disease: A Focus on Equity

Nov 2020

This webinar will define how Alzheimer’s disease affects underserved communities; share opportunities to create more equitable, ethical, and inclusive value frameworks; and educate on the community’s role in solving this problem.

Valuing Future Alzheimer’s Disease Medicines: Extending the Paradigm

Oct 2020

This webinar seeks to explore some of these broader elements within the context of evolving value assessment and considers how they may meaningfully be incorporated to facilitate a more holistic approach to valuing medical innovation.

Need More Information or Have Questions?

Contact us for more information on ISPOR education and training.

Contact Us

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×